As an adjunctive treatment for "off" episodes in Parkinson’s disease, safinamide’s clinical efficacy, medical insurance coverage, and pricing are common concerns for patients and their families.
I. Evaluation of Therapeutic Effect
1. Clinical Research Evidence
(1) Two multinational, randomized, double-blind, placebo-controlled studies (Study 1 and Study 2) with a 24-week duration evaluated the efficacy of safinamide.
(2) All study subjects were Parkinson’s disease patients treated with levodopa/carbidopa who experienced "off" episodes.
(3) Results showed a significant reduction in "off" time and an improvement in motor function scores (UPDRS III) in both treatment groups.
2. Characteristics of Efficacy
(1) Sustained effect: Efficacy was observed at all time points after treatment initiation and maintained through 24 weeks.
(2) Minimal dose difference: The extension of "on" time was similar between the 50 mg and 100 mg doses, though the 100 mg group showed slight superiority in some indicators.
(3) No aggravation of dyskinesia: The therapeutic effect was mainly reflected in the prolongation of "on" time without troublesome dyskinesia, with no significant worsening of dyskinesia.
3. Common Adverse Reactions
(1) The most frequent adverse reactions were dyskinesia, falls, nausea, and insomnia, with higher incidence rates than in the placebo group.
(2) Most adverse reactions were mild to moderate and could be alleviated by dose adjustment or symptomatic management.
II. Medical Insurance Coverage
1. U.S. Market
Safinamide was approved by the U.S. Food and Drug Administration (FDA) in 2017 and is available as a prescription drug.
2. Chinese Market
(1) As of April 2026, safinamide has not been officially launched in Chinese mainland, hence it is not included in the National Reimbursement Drug List.
(2) Some patients may obtain the drug through overseas purchasing or clinical trials, but attention should be paid to the legality of drug sources and medication safety.
(3) For countries and regions where the drug is already marketed, patients may consult local medical insurance authorities for specific reimbursement policies.
3. Patient Assistance Programs
Original research pharmaceutical companies or authorized distributors may offer patient assistance programs to provide drug support for eligible low-income or uninsured patients.
III. Pricing Information
1. U.S. Market Price
In the United States, the price of a single box (30 tablets) of safinamide generally ranges from 800 to 1,200 U.S. dollars, varying by pharmacy, insurance negotiations, and patient out-of-pocket ratios.
2. Factors Affecting Pricing
(1) Dosage and quantity: The average price per tablet differs between 30-tablet and 90-tablet packs, with larger packages usually more cost-effective.
(2) Insurance type: Insurance coverage and out-of-pocket ratios directly affect patient expenses.
(3) Pharmacy channels: Retail pharmacies, mail-order pharmacies, and specialty pharmacies have different pricing.
(4) Patent status: The originator brand is priced higher; future launch of generic versions may lead to price reductions.
3. Considerations for Access Costs
When considering pharmacotherapy, patients should account for the following costs in addition to the drug price itself:
(1) Fees for medical consultations and monitoring (e.g., blood pressure monitoring, ophthalmic examinations).
(2) Additional expenses from adjustments to concomitant medications.
(3) For overseas purchasing, logistics, tariffs, and storage requirements should also be considered.
